Literature DB >> 10551789

First trimester screening for aneuploidy: serum biochemical markers.

J A Canick1, L H Kellner.   

Abstract

The article reviews screening for Down syndrome in the first trimester (8-13 gestational weeks) with maternal serum analytes. In the first trimester, 2 serum markers stand out: pregnancy-associated plasma protein-A, a large glycoprotein tetramer, and free beta-human chorionic gonadotropin (beta-hCG), 1 of the 2 subunits of the glycoprotein hormone hCG. Some data indicate that hCG itself may be as effective as free beta-hCG in the first trimester. Maternal serum levels of pregnancy-associated plasma protein-A are low and free beta-hCG are high (consensus multiple of the medians, 0.4 and 1.8, respectively) in Down syndrome pregnancy. The consensus estimate of screening performance by using pregnancy-associated plasma protein-A and free beta-hCG in combination with maternal age is 60% detection rate at a 5% false positive rate. This is similar to the screening performance of second trimester double markers, but not as good as the screening performance of second trimester triple or quad markers. For this reason, first trimester screening with serum markers alone cannot be recommended except in cases in which second trimester screening cannot be done.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551789     DOI: 10.1016/s0146-0005(99)80002-0

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  5 in total

1.  Prenatal diagnosis and fetal therapy--what lies in future?

Authors:  J Mauldin
Journal:  Indian J Pediatr       Date:  2000-12       Impact factor: 1.967

2.  The associations of nuchal translucency and fetal abnormalities; significance and implications.

Authors:  Shaista Salman Guraya
Journal:  J Clin Diagn Res       Date:  2013-03-20

3.  The assessment of nuchal translucency and serum markers for down syndrome screening with ductus venosus Doppler measurements in the first trimester.

Authors:  Ozlem Ozer; Cenk N Sayın; Füsun G Varol
Journal:  J Turk Ger Gynecol Assoc       Date:  2010-12-01

4.  A toolkit for the application of placental-fetal molecular biomarkers in epidemiologic studies of the fetal origins of chronic disease.

Authors:  Jennifer J Adibi; Alexander J Layden; Qing Yin; Xiaoshuang Xun; Shyamal Peddada; Rahel L Birru
Journal:  Curr Epidemiol Rep       Date:  2020-12-28

Review 5.  Non-Invasive Screening Tools for Down's Syndrome: A Review.

Authors:  Kelly A Sillence; Tracey E Madgett; Llinos A Roberts; Timothy G Overton; Neil D Avent
Journal:  Diagnostics (Basel)       Date:  2013-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.